Japan Committee Recommends Lecanemab Approval

 
• By Lisa Takagi

An advisory committee of Japan’s MHLW has given a favorable opinion for the approval of Eisai's Alzheimer's drug lecanemab, setting the stage for a possible full official approval in September, after which it would be co-commercialized with global partner Biogen.

Japan’s AD population has grown over years. Lecanemab was granted Priority Review in January.
Japan’s AD population has grown over recent years • Source: Shutterstock

More from Japan

More from Asia